Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cebranopadol versus oxycodone ventilatory response to hypercapnia study in healthy volunteers
NL-OMON51788Active, not recruiting
- Sponsor
- Park Therapeutics
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of cebranopadol and oxycodone in acute pain and chronic pain (6 arms), sponsored by Park Therapeutics. Primary endpoint: Ventilatory response to hypercapnia by maximum decrease in minute ventilation. Started Jul 2022; status: active, not recruiting.
02
Drugs
cebranopadoloxycodone
03
Conditions
acute painchronic pain
Beyond the preview
Go deeper on NL-OMON51788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51788.